Advertisement
CYPH vs INKT
Which Stock Would AI Choose? Cypherpunk Technologies (CYPH) vs. MiNK Therapeutics (INKT) Stock Comparison
Key Takeaways
- CYPH and INKT operate in fundamentally different arenas: CYPH is a privacy-technology and digital-asset treasury company anchored by Zcash (ZEC), while INKT is a clinical-stage biopharmaceutical company developing iNKT cell therapies.
- CYPH has delivered pronounced share-price gains and volatility tied to Zcash price swings and a new mining business, whereas INKT trades as a smaller, pre-revenue biotech with binary clinical catalysts.
- CYPH recently swung to a quarterly profit driven by unrealized ZEC treasury gains; INKT continues to report operating losses as it advances its pipeline.
- Both stocks carry elevated risk profiles, though the sources of risk differ: digital-asset price volatility for CYPH versus clinical, regulatory, and funding risk for INKT.
- For further context on these names, explore CYPH Major News and CYPH Today's Price Move, as well as INKT Major News and INKT Today's Price Move.
- To see how AI-driven strategies are positioning across the broader market, explore Trending AI Robots.
Introduction
This stock comparison examines two very different small-cap names: CYPH, representing Cypherpunk Technologies, and INKT, representing MiNK Therapeutics. The two companies share little in the way of industry overlap, yet both attract investors drawn to asymmetric, catalyst-driven opportunities. CYPH offers exposure to the Zcash ecosystem through a digital-asset treasury and a newly launched mining operation, while INKT offers exposure to early-stage oncology and immunotherapy development. Traders focused on momentum and digital-asset themes may favor the former, while longer-horizon, risk-tolerant investors interested in clinical milestones may find the latter more relevant. This comparison evaluates relative performance, market positioning, and the factors currently shaping sentiment around each name.
CYPH Overview and Recent Performance
CYPH, formerly Leap Therapeutics, rebranded as Cypherpunk Technologies in November 2025 and repositioned around a Zcash (ZEC) digital-asset treasury strategy, backed in part by Winklevoss Capital. The company has since expanded beyond simply holding ZEC: it launched Cypherpunk Mining, described as the world's largest Zcash mining fleet, with roughly 4.2 GSol/s of hashrate representing approximately 18% of the Zcash network. The company also holds a large ZEC position, reported at more than 320,000 ZEC, or nearly 2% of circulating supply.
Recent market activity has been volatile. The stock climbed sharply over recent months, and the company swung to a second-quarter net profit of approximately $39.4 million, largely driven by a $46 million unrealized gain on its ZEC holdings. Cantor Fitzgerald raised its price target to $4.90 from $1.60 while maintaining an Overweight rating. The company also continues to develop oncology assets through its Leap Therapeutics subsidiary, including sirexatamab for colorectal cancer. Sentiment is heavily influenced by Zcash price movements, making CYPH behave more like a leveraged proxy for digital-asset momentum than a traditional operating business.
INKT Overview and Recent Performance
INKT is MiNK Therapeutics, a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its lead candidate, agenT-797, is an unmodified iNKT cell therapy, and the company continues to advance its pipeline through early-stage clinical development.
As a pre-revenue biotech, INKT's stock performance is driven primarily by clinical data readouts, regulatory progress, and funding developments rather than recurring earnings. The company maintains a small market capitalization and reports ongoing operating losses, with a limited cash runway typical of early-stage developers. Recent market activity has reflected the broader uncertainty facing small-cap biotechs, with the stock trading well below its 52-week high. Analyst coverage remains limited, though HC Wainwright has reiterated a Buy rating with a $35 price target, reflecting the long-dated, binary nature of the company's value proposition. Unlike CYPH, INKT's relative performance is less correlated to digital-asset prices and more dependent on scientific and clinical milestones.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a larger universe of hundreds of available bots that collectively trade thousands of different tickers. Only the bots best suited to current market conditions earn a place in this section. Each bot operates with its own trading style, strategy, timeframe, performance record, and set of tickers, allowing users to compare statistics and select an approach aligned with their objectives. Because the platform evaluates bots against prevailing market conditions, the featured selections are designed to reflect strategies that are currently among the most relevant. For investors seeking a systematic, data-driven way to monitor opportunities across names like CYPH and INKT, exploring Trending AI Robots can offer useful, ongoing perspective.
Head-to-Head Comparison
The clearest contrast between the two is business model. CYPH functions as a hybrid digital-asset treasury and mining operator with a legacy biotech arm, making its financial results highly sensitive to Zcash price fluctuations. INKT is a pure-play clinical biotech whose value hinges on trial data and regulatory outcomes. Growth drivers also differ: CYPH's momentum is tied to ZEC appreciation, mining economics, and network security, while INKT's is tied to clinical efficacy and eventual commercialization of iNKT therapies.
Risk profiles diverge accordingly. CYPH faces digital-asset volatility, share dilution, and Nasdaq bid-price compliance considerations. INKT faces clinical failure risk, funding needs, and the long timelines inherent to drug development. Sector exposure is also distinct, with CYPH spanning digital assets and healthcare and INKT concentrated in biotechnology. On relative performance, CYPH has exhibited stronger recent upward momentum alongside greater volatility, whereas INKT has traded more range-bound with occasional binary swings. Market sentiment favors CYPH's narrative momentum, but that momentum is more tightly coupled to an external asset's price than to INKT's internally driven clinical catalysts.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely express a near-term preference for CYPH, given its stronger trend consistency, positive earnings inflection, and a catalyst-rich setup spanning Zcash appreciation and mining expansion. The caveat is elevated volatility and a performance profile tied to digital-asset prices, which introduces instability risk. INKT presents a more binary, long-dated thesis with less immediate trend confirmation. While neither name is low-risk, CYPH's current relative positioning appears more favorable on trend and momentum metrics, though its stability is more conditional. This assessment reflects probabilistic, data-driven positioning rather than a definitive recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYPH is a Buy and INKT is a Hold.
Momentum Indicator for CYPH turns negative, indicating new downward trend
CYPH saw its Momentum Indicator move below the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned negative. In 68 of the 75 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CYPH turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 34 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
CYPH moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CYPH crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CYPH entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +21.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYPH advanced for three days, in 216 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CYPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.228) is normal, around the industry mean (2.412). P/E Ratio (4.500) is within average values for comparable stocks, (-2.386). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.000) settles around the average of (0.270) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (15.694).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
INKT in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 07, 2026
INKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 34 cases where INKT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INKT's RSI Oscillator exited the oversold zone, 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 67 cases where INKT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for INKT just turned positive on November 11, 2026. Looking at past instances where INKT's MACD turned positive, the stock continued to rise in 40 of 53 cases over the following month. The odds of a continued upward trend are 75%.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where INKT advanced for three days, in 167 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INKT as a result. In 101 of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
INKT moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INKT crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
The 50-day moving average for INKT moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for INKT entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.692) is normal, around the industry mean (3.498). P/E Ratio (-4.283) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. INKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CYPH | ||
|---|---|---|
OUTLOOK RATING 1..100 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 91 | |
PRICE GROWTH RATING 1..100 | 34 | |
P/E GROWTH RATING 1..100 | 92 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CYPH | INKT | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 75% |
| TrendWeek ODDS (%) | 1 day ago 89% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 88% |
| Advances ODDS (%) | 8 days ago 89% | 9 days ago 77% |
| Declines ODDS (%) | 1 day ago 90% | 7 days ago 90% |
| BollingerBands ODDS (%) | N/A | 6 days ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CYPH’s FA Score shows that 0 FA rating(s) are green while INKT’s FA Score has 1 green FA rating(s).
- CYPH’s FA Score: 0 green, 5 red.
- INKT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CYPH’s TA Score shows that 2 TA indicator(s) are bullish while INKT’s TA Score has 5 bullish TA indicator(s).
- CYPH’s TA Score: 2 bullish, 6 bearish.
- INKT’s TA Score: 5 bullish, 6 bearish.
Price Growth
CYPH (@Investment Managers) experienced а -30.31% price change this week, while INKT (@Biotechnology) price change was -3.71% for the same time period.
The average weekly price growth across all stocks in the @Investment Managers industry was -2.51%. For the same industry, the average monthly price growth was -2.71%, and the average quarterly price growth was -1.65%.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
INKT is expected to report earnings on Mar 23, 2027.
Industries' Descriptions
@Investment Managers (-2.51% weekly)Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CYPH and
Correlation & Price change
A.I.dvisor indicates that over the last year, CYPH has been loosely correlated with INKT. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYPH jumps, then INKT could also see price increases.
| Ticker / NAME | Correlation To CYPH | 1D Price Change % | ||
|---|---|---|---|---|
| CYPH | 100% | -6.10% | ||
| INKT - CYPH | 42% Loosely correlated | +3.60% | ||
| AXON - CYPH | 40% Loosely correlated | +4.26% | ||
| FWDI - CYPH | 37% Loosely correlated | +2.29% | ||
| SABS - CYPH | 36% Loosely correlated | +1.30% | ||
| AMRN - CYPH | 35% Loosely correlated | -0.34% | ||
More | ||||
INKT and
Correlation & Price change
A.I.dvisor indicates that over the last year, INKT has been closely correlated with REVB. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if INKT jumps, then REVB could also see price increases.
| Ticker / NAME | Correlation To INKT | 1D Price Change % | ||
|---|---|---|---|---|
| INKT | 100% | +3.60% | ||
| REVB - INKT | 66% Closely correlated | +5.96% | ||
| KAPA - INKT | 50% Loosely correlated | +7.57% | ||
| RAIN - INKT | 43% Loosely correlated | +2.86% | ||
| CYPH - INKT | 42% Loosely correlated | -6.10% | ||
| PTHS - INKT | 41% Loosely correlated | +5.51% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| APIE | 38.40 | 0.19 | +0.50% |
| ActivePassive International Equity ETF (APIE) | |||
| XW | 22.84 | N/A | N/A |
| Corgi Ex-U.S. Equities 2x Daily ETF (XW) | |||
| OACP | 21.99 | N/A | -0.02% |
| OneAscent Core Plus Bond ETF (OACP) | |||
| VBCE | 73.35 | -0.06 | -0.08% |
| Vanguard Target Maturity 2031 Corporate Bond ETF (VBCE) | |||
| UST | 39.51 | -0.08 | -0.20% |
| ProShares Ultra 7-10 Year Treasury (UST) | |||